What are the side effects and specific treatment measures and precautions of Suvotinib?

The side effects of Suvotinib mainly include rash, diarrhea, anemia, paronychia, oral mucositis, increased blood creatinine, nausea, loss of appetite, vomiting and increased lipase, etc., which require targeted treatment according to different symptoms.

Side effects of Suvotinib

The most common side effects in patients treated with are rash, diarrhea, increased blood creatine phosphokinase, anemia, paronychia, oral mucositis, increased serum creatinine, nausea, loss of appetite, vomiting, and elevated lipase. Serious adverse reactions were reported in 10.7% of patients, of which ≥2% reported serious adverse reactions involving interstitial lung disease/pulmonary inflammation.

31.3% of patients suspended treatment due to drug side effects, resulting in side effects such as diarrhea, elevated blood creatine phosphokinase, rash, loss of appetite, elevated lipase, vomiting, anemia, and keratitis. 20% of patients reduced the dosage due to drug side effects, and the side effects leading to dosage reduction were increased blood creatine phosphokinase, diarrhea, oral mucositis, and paronychia. 5.3% of patients discontinued treatment due to drug side effects, and the side effects leading to treatment discontinuation were interstitial lung disease/pulmonary inflammation.

Specific treatment measures for Suvotinib

1. Fatigue: It is recommended to pay attention to rest and arrange work and rest time reasonably to avoid fatigue.

2. Loss of appetite: It is recommended to eat small amounts frequently and choose foods that are easy to digest.

3. Diarrhea: It is recommended to drink more water to avoid dehydration. If the diarrhea is severe or persistent, you can use anti-diarrheal drugs such as probiotics or montmorillonite powder as directed by your doctor. When abnormally increased bowel frequency, soft or loose stools occur, antidiarrheal treatment should be initiated as early as possible along with dietary modification and other supportive care.

4. Rash: Keep skin moisturized, avoid direct sunlight, use mild care products, and avoid excessive scratching of rash.

5. Oral ulcers: Maintain oral hygiene, rinse your mouth promptly after meals, and avoid eating hot or hard food.

6. Nausea or vomiting: You can use antiemetics and anti-nausea drugs as directed by your doctor to relieve symptoms.

7. Keratitis: If ulcerative keratitis is diagnosed, suvotinib needs to be permanently discontinued. You should be careful when driving or operating machinery while taking this product, and avoid the above operations when you are tired.

Recommended dose of Suvotinib

The recommended dose of Suvotinib is 300 mg, taken once a day, and should be taken orally at a fixed time every day, and the entire tablet should be taken with water.

Measures for handling missed doses

If Suvotinib is not taken at the planned time, it should be taken within 4 hours of the planned taking time, and should not be taken after 4 hours.

Dose adjustment

If dose reduction is required, the initial dose reduction should be reduced to 200 mg once daily. If the dose needs to be reduced again, it can be reduced to 150 mg once daily.

Dose adjustment when coadministered with CYP3A inhibitors

Avoid coadministration of suvotinib with strong CYP3A inhibitors. If this cannot be avoided, the starting dose of suvotinib should be adjusted to 200 mg once daily. After stopping taking a strong CYP3A inhibitor, the suvotinib dose can be resumed to the dose before starting the CYP3A inhibitor.

Suvotinib has a relatively high disease control rate

In the phase 2, single-group, multi-center study of WONKONG-6, the latest research data showed that the objective response rate in the suvotinib treatment group was 60.8%, and the disease control rate was as high as 87.6%, indicating that nearly 90% of patients treated with suvotinib had tumors shrunk or stabilized to varying degrees. If you want to know more about the efficacy of suvotinib, you can refer to the article:

Precautions for taking suvotinib

1. Men or women of childbearing age should avoid childbirth while taking suvotinib, and should still take effective contraceptive measures for a certain period of time after completing treatment. Women should use contraception for at least 2 months, and men should use contraception for at least 6 months.

2. Suvotinib taken by pregnant women may cause harm to the fetus. Suvotinib should not be taken during pregnancy unless clinical circumstances require it.

3. Breastfeeding should be stopped during suvotinib treatment.

4. During suvotinib treatment, factors such as alcoholism, overwork, and inattention to diet should also be avoided to maintain good physical condition.

5. The safety and effectiveness of suvotinib in children or adolescents under 18 years of age have not been determined.

Summary

The emergence of the new drug suvotinib has given patients with lung cancer a better treatment option. Patients must not blindly self-medicate and must strictly follow the doctor's instructions. If there are special circumstances, such as side effects, they should seek medical treatment in time.

Related hot article recommendations: